Among men with distant, de novo, metastatic prostate cancer (PCa) undergoing treatment with androgen-deprivation therapy (ADT), those of Asian ethnicity have superior median overall and PCa-specific survival to men of any other race, according to a study published in Cancer.1
Researchers examined men who were diagnosed with distant, de novo, metastatic PCa from 2004 to 2012 through the Surveillance, Epidemiology, and End Results (SEER) registry to determine the responsiveness of metastatic PCa to ADT based on race.
Throughout the entire SEER registry, 4.2% of those diagnosed with distant, de novo, metastatic PCa were non-Hispanic Caucasian, 5.8% were Hispanic Caucasian, 5.7% were African American, 5.5% were Asians/Pacific Islanders, and 8.8% were American Indians/Alaska Natives.
Median overall survival was superior among Asian men at 30 months as well as superior median PCa-specific mortality at 54 months compared to men of other ethnicities.
Upon retrospective review of the E3805 clinical trial, which included few Asian participants, the researchers also found that chemohormonal therapy was associated with a median overall survival of 58.1 months among non-Hispanic Caucasians and 57.6 months among African Americans.
“Non-Hispanic whites and blacks who receive treatment with ADT or chemohormonal therapy have comparable outcomes,” the authors concluded.
- Bernard B, Muralidhar V, Chen Y, et al. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer. 2017 Jan 5. doi: 10.1002/cncr.30503 [Epub ahead of print]